Relay Therapeutics, Inc. entered into an Underwriting Agreement with Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters listed on Schedule 1 thereto
Relay Therapeutics, Inc. entered into an Underwriting Agreement with Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters listed on Schedule 1 thereto
Under the DESRES Agreement, we agreed to collaborate with D. E. Shaw Research to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused…
Reciprocal relationship from PVLA graph: ion, future events, or otherwise, except as may be required by law. SUMMARY OF PRINCIPAL RISK FACTORS Below is a summary of material factors that make an inve…
Braftovi (encorafenib), a BRAF inhibitor indicated for use in combination with Mektovi (binimetinib), a MEK inhibitor, both marketed by Pfizer for the treatment of metastatic melanoma with a BRAF V60…
Reciprocal relationship from PFE graph: Reciprocal relationship from RLAY graph: Braftovi (encorafenib), a BRAF inhibitor indicated for use in combination with Mektovi (binimetinib), a MEK inhibitor,…
During the three months ended March 31, 2026, the Company recognized $3.0 million of revenue from the Elevar Agreement, specifically upon receipt of certain milestone payments.
Under the terms of the Genentech Agreement, we received $75.0 million in an upfront payment in 2021, as well as $45.0 million in milestone payments from Genentech as of December 31, 2024.
ctively. Elevar Therapeutics, Inc. In December 2024, the Company and Elevar Therapeutics, Inc. ("Elevar") entered into the Exclusive License Agreement ("Elevar Agreement"), pursuant to which Elevar w…
Reciprocal relationship from PVLA graph: ting approval is obtained. We believe that this strategy allows us to maintain a more efficient infrastructure by eliminating the need for us to invest in our…
Relay Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
RLAY-DEBT-12216
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2020-12-31.
RLAY-DEBT
Debt stack $31.6M
90%
Market cache reports total debt of $31.6M.
RLAY-DEBT-12215
Warrants outstanding: 2836000
90%
xbrl warrant detail from xbrl 2021-12-31.
Relay Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Relay Therapeutics, Inc..
Relay Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
RLAY-OWNER-SB-INVESTMENT-ADVISERS-UK-LTD
SB INVESTMENT ADVISERS (UK) LTD
90%
13F overlay lists SB INVESTMENT ADVISERS (UK) LTD as top holder; 244 tracked holders.
Relay Therapeutics, Inc. Extended Supply Chain Network
